8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Feb 26, 2026·SEC
OPKO Health, Inc.(OPK)Earnings, Financials & Key Ratios
OPK•NASDAQ
$1.12
$846M mkt cap·Price updated May 6, 2026
AboutOPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.Show more
- Revenue$607M-14.9%
- EBITDA-$127M-136.3%
- Net Income-$226M-324.1%
- EPS (Diluted)-0.30-291.1%
- Gross Margin21.1%-51.6%
- EBITDA Margin-20.99%-177.7%
- Operating Margin-36.08%-69.2%
- Net Margin-37.2%-398.4%
- ROE-17.14%-343.6%
- ROIC-11.86%-58.9%
- Debt/Equity0.34-7.4%
- Interest Coverage-1.38-277.1%
OPK Key Insights
OPKO Health, Inc. (OPK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 15.8% over 5 years
- ✗Shares diluted 10.3% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OPK Price & Volume
OPKO Health, Inc. (OPK) stock price & volume — 10-year historical chart
Loading chart...
OPK Growth Metrics
OPKO Health, Inc. (OPK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.13%
5 Years-15.82%
3 Years-15.45%
TTM-15.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-446.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-369.19%
Return on Capital
10 Years-7.04%
5 Years-7.64%
3 Years-9.28%
Last Year-11.55%
OPK Recent Earnings
OPKO Health, Inc. (OPK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 28, 2026EPS
$0.07
Est $0.07
+0.0%
Revenue
$124M
Est $131M
-4.8%
Q1 2026
Feb 26, 2026EPS
$0.04
Est $0.07
+42.9%
Revenue
$149M
Est $140M
+6.3%
Q4 2025
Oct 29, 2025EPS
$0.03
Est $0.02
+250.0%
Revenue
$152M
Est $140M
+8.5%
Q3 2025
Jul 31, 2025EPS
$0.19
Est $0.12
-58.3%
Revenue
$157M
Est $166M
-5.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.07vs $0.07+0.0% | $124Mvs $131M-4.8% |
| Q1 2026 | Feb 26, 2026 | $0.04vs $0.07+42.9% | $149Mvs $140M+6.3% |
| Q4 2025 | Oct 29, 2025 | $0.03vs $0.02+250.0% | $152Mvs $140M+8.5% |
| Q3 2025 | Jul 31, 2025 | $0.19vs $0.12-58.3% | $157Mvs $166M-5.4% |
Based on last 12 quarters of dataView full earnings history →
OPK Peer Comparison
OPKO Health, Inc. (OPK) competitors in Clinical and Specialty Lab Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 LH | 21.14B | 256.93 | 24.56 | 7.25% | 6.66% | 10.89% | 0.83 | |
 DGX | 20.93B | 189.13 | 21.61 | 11.78% | 9.08% | 13.8% | 0.95 | |
 BIO | 6.99B | 259.02 | 9.29 | 0.65% | 6.52% | 2.4% | 0.21 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 |
Compare OPK vs Peers
OPKO Health, Inc. (OPK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OPK Income Statement
OPKO Health, Inc. (OPK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 966.01M | 990.3M | 901.93M | 1.44B | 1.77B | 1B | 863.5M | 713.14M | 606.88M | 581.17M |
| Revenue Growth % | -20.93% | 2.51% | -8.92% | 59.15% | 23.64% | -43.42% | -14.01% | -17.41% | -14.9% | -15.7% |
| Cost of Goods Sold | 620.13M | 604.6M | 572.48M | 894.41M | 1.19B | 715.98M | 545.37M | 402.11M | 478.83M | 303.95M |
| COGS % of Revenue | 64.2% | 61.05% | 63.47% | 62.31% | 67.23% | 71.3% | 63.16% | 56.39% | 78.9% | - |
| Gross Profit | 345.88M▲ 0% | 385.7M▲ 11.5% | 329.45M▼ 14.6% | 541M▲ 64.2% | 581.52M▲ 7.5% | 288.22M▼ 50.4% | 318.13M▲ 10.4% | 311.03M▼ 2.2% | 128.05M▼ 58.8% | 277.22M▲ 0% |
| Gross Margin % | 35.8% | 38.95% | 36.53% | 37.69% | 32.77% | 28.7% | 36.84% | 43.61% | 21.1% | 47.7% |
| Gross Profit Growth % | -43.32% | 11.51% | -14.58% | 64.21% | 7.49% | -50.44% | 10.38% | -2.23% | -58.83% | - |
| Operating Expenses | 625.74M | 551.9M | 603.5M | 483.29M | 562.77M | 514.47M | 475.15M | 463.1M | 347.04M | 378.46M |
| OpEx % of Revenue | 64.78% | 55.73% | 66.91% | 33.67% | 31.71% | 51.23% | 55.03% | 64.94% | 57.18% | - |
| Selling, General & Admin | 414.63M | 358.4M | 343.31M | 355.57M | 468.86M | 372.67M | 300.56M | 304.22M | 223.03M | 212.51M |
| SG&A % of Revenue | 42.92% | 36.19% | 38.06% | 24.77% | 26.42% | 37.11% | 34.81% | 42.66% | 36.75% | - |
| Research & Development | 126.44M | 135.69M | 117.87M | 75.32M | 76.85M | 73.89M | 89.59M | 105.21M | 124.08M | 122.42M |
| R&D % of Revenue | 13.09% | 13.7% | 13.07% | 5.25% | 4.33% | 7.36% | 10.38% | 14.75% | 20.44% | - |
| Other Operating Expenses | 81.25M | 72.89M | 142.33M | 52.4M | 17.07M | 67.91M | 85M | 53.66M | -72K | 2M |
| Operating Income | -276.44M▲ 0% | -171.2M▲ 38.1% | -274.05M▼ 60.1% | 57.71M▲ 121.1% | 18.75M▼ 67.5% | -226.25M▼ 1306.7% | -157.02M▲ 30.6% | -152.06M▲ 3.2% | -218.99M▼ 44.0% | -101.24M▲ 0% |
| Operating Margin % | -28.62% | -17.29% | -30.38% | 4.02% | 1.06% | -22.53% | -18.18% | -21.32% | -36.08% | -17.42% |
| Operating Income Growth % | -277.27% | 38.07% | -60.08% | 121.06% | -67.51% | -1306.68% | 30.6% | 3.16% | -44.01% | - |
| EBITDA | -174.35M | -73.85M | -180.25M | 143.08M | 97.47M | -117.6M | -51.72M | -53.89M | -127.36M | -33.1M |
| EBITDA Margin % | -18.05% | -7.46% | -19.98% | 9.97% | 5.49% | -11.71% | -5.99% | -7.56% | -20.99% | -5.7% |
| EBITDA Growth % | -848.25% | 57.64% | -144.06% | 179.38% | -31.88% | -220.66% | 56.02% | -4.19% | -136.33% | 36.24% |
| D&A (Non-Cash Add-back) | 102.09M | 97.34M | 93.81M | 85.36M | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M | 68.14M |
| EBIT | -265.32M | -165.38M | -283.45M | 70.62M | 4.86M | -379.46M | -170.81M | 37.1M | -140.17M | -82.2M |
| Net Interest Income | -5.99M | -10.65M | -19.81M | -21.78M | -18.85M | -10.07M | -9.52M | -39.04M | -88.61M | -77.83M |
| Interest Income | 610K | 1.24M | 1.71M | 152K | 28K | 1.98M | 3.98M | 8.43M | 12.65M | 10.97M |
| Interest Expense | 6.6M | 11.89M | 21.52M | 21.93M | 18.88M | 12.06M | 13.51M | 47.47M | 101.26M | 74.85M |
| Other Income/Expense | 4.52M | -6.07M | -30.91M | -9.51M | -33.4M | -165.65M | -27.41M | 141.7M | -22.41M | -127.7M |
| Pretax Income | -271.92M▲ 0% | -177.27M▲ 34.8% | -304.96M▼ 72.0% | 48.2M▲ 115.8% | -14.65M▼ 130.4% | -391.9M▼ 2574.4% | -184.43M▲ 52.9% | -10.36M▲ 94.4% | -241.43M▼ 2230.0% | -228.94M▲ 0% |
| Pretax Margin % | -28.15% | -17.9% | -33.81% | 3.36% | -0.83% | -39.03% | -21.36% | -1.45% | -39.78% | -39.39% |
| Income Tax | 18.86M | -38.7M | 7.06M | 17.62M | 15.49M | -63.5M | 4.44M | 42.84M | -15.71M | -16.09M |
| Effective Tax Rate % | -6.93% | 21.83% | -2.32% | 36.55% | -105.7% | 16.2% | -2.41% | -413.47% | 6.51% | 7.03% |
| Net Income | -305.25M▲ 0% | -153.04M▲ 49.9% | -314.93M▼ 105.8% | 30.59M▲ 109.7% | -30.14M▼ 198.6% | -328.4M▼ 989.5% | -188.86M▲ 42.5% | -53.22M▲ 71.8% | -225.73M▼ 324.1% | -212.96M▲ 0% |
| Net Margin % | -31.6% | -15.45% | -34.92% | 2.13% | -1.7% | -32.7% | -21.87% | -7.46% | -37.2% | -36.64% |
| Net Income Growth % | -531.22% | 49.86% | -105.78% | 109.71% | -198.55% | -989.49% | 42.49% | 71.82% | -324.12% | -446.03% |
| Net Income (Continuing) | -305.25M | -153.04M | -314.93M | 30.59M | -30.14M | -328.4M | -188.86M | -53.21M | -225.72M | -212.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.55▲ 0% | -0.27▲ 50.9% | -0.53▼ 96.3% | 0.05▲ 109.0% | -0.05▼ 195.4% | -0.46▼ 911.0% | -0.25▲ 45.7% | -0.08▲ 69.3% | -0.30▼ 291.1% | -0.28▲ 0% |
| EPS Growth % | -1000% | 50.91% | -96.3% | 109% | -195.39% | -910.99% | 45.65% | 69.32% | -291.13% | -369.19% |
| EPS (Basic) | -0.55 | -0.27 | -0.53 | 0.05 | -0.05 | -0.46 | -0.25 | -0.08 | -0.29 | - |
| Diluted Shares Outstanding | 559.16M | 566.67M | 595.45M | 640.65M | 648.08M | 719.06M | 751.77M | 694.02M | 765.52M | 758.88M |
| Basic Shares Outstanding | 555M | 563.14M | 595.45M | 640.65M | 648.08M | 719.06M | 751.77M | 694.02M | 765.52M | 758.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OPK Balance Sheet
OPKO Health, Inc. (OPK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 348.86M | 317.7M | 324.05M | 523.18M | 823.01M | 394.52M | 309.48M | 662.09M | 581.88M | 535.36M |
| Cash & Short-Term Investments | 91.5M | 96.5M | 85.45M | 72.21M | 134.71M | 153.19M | 95.88M | 431.94M | 369.07M | 341.88M |
| Cash Only | 91.5M | 96.47M | 85.45M | 72.21M | 134.71M | 153.19M | 95.88M | 431.94M | 369.07M | 341.88M |
| Short-Term Investments | 0 | 27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 187.05M | 161.98M | 157.69M | 302.26M | 265.59M | 148.61M | 130.2M | 152.05M | 90.25M | 79.64M |
| Days Sales Outstanding | 70.68 | 59.7 | 63.81 | 76.86 | 54.62 | 54.02 | 55.04 | 77.82 | 54.28 | 67.33 |
| Inventory | 49.33M | 42.3M | 53.43M | 132.34M | 86.5M | 74.06M | 65.7M | 56.8M | 65.82M | 64.4M |
| Days Inventory Outstanding | 29.04 | 25.54 | 34.07 | 54.01 | 26.46 | 37.76 | 43.97 | 51.56 | 50.18 | 78.51 |
| Other Current Assets | 9.24M | 3.85M | 15.84M | 5.31M | 321.19M | 6.25M | 7.67M | 10.71M | 56.73M | 49.45M |
| Total Non-Current Assets | 2.24B | 2.13B | 1.99B | 1.95B | 1.58B | 1.77B | 1.7B | 1.54B | 1.35B | 1.32B |
| Property, Plant & Equipment | 146.56M | 144.67M | 166.49M | 178.29M | 123.95M | 121.6M | 143.52M | 124.14M | 120.86M | 118.39M |
| Fixed Asset Turnover | 6.59x | 6.85x | 5.42x | 8.05x | 14.32x | 8.26x | 6.02x | 5.74x | 5.02x | 4.83x |
| Goodwill | 717.1M | 700.19M | 671.94M | 680.6M | 520.6M | 595.85M | 598.26M | 529.25M | 484.29M | 482.27M |
| Intangible Assets | 1.33B | 1.25B | 1.12B | 1.07B | 911.88M | 1.02B | 935.28M | 811.61M | 516.28M | 496.35M |
| Long-Term Investments | 40.64M | 31.23M | 20.75M | 15.73M | 10.71M | 28.05M | 16.08M | 54.58M | 14.17M | 51.1M |
| Other Non-Current Assets | 5.62M | 797.6M | 6.89M | 10.06M | 9.55M | 8.71M | 9.08M | 18.54M | 214.47M | 468.18M |
| Total Assets | 2.59B▲ 0% | 2.45B▼ 5.4% | 2.31B▼ 5.8% | 2.47B▲ 7.1% | 2.4B▼ 3.0% | 2.17B▼ 9.7% | 2.01B▼ 7.2% | 2.2B▲ 9.4% | 1.93B▼ 12.2% | 1.86B▲ 0% |
| Asset Turnover | 0.37x | 0.40x | 0.39x | 0.58x | 0.74x | 0.46x | 0.43x | 0.32x | 0.31x | 0.30x |
| Asset Growth % | -6.38% | -5.36% | -5.79% | 7.09% | -2.97% | -9.69% | -7.18% | 9.37% | -12.19% | -36.85% |
| Total Current Liabilities | 312.03M | 256.8M | 249.12M | 375.48M | 330.01M | 213.48M | 200.05M | 193.1M | 146.68M | 148.38M |
| Accounts Payable | 74.31M | 47.4M | 62.54M | 100.88M | 82.04M | 66.99M | 69.68M | 47.07M | 41.1M | 44.18M |
| Days Payables Outstanding | 43.74 | 28.61 | 39.87 | 41.17 | 25.1 | 34.15 | 46.63 | 42.73 | 31.33 | 57.88 |
| Short-Term Debt | 11.93M | 37.41M | 24.4M | 36.18M | 14.69M | 36.59M | 27.29M | 15.02M | 22.86M | 20.73M |
| Deferred Revenue (Current) | 56.88M | 63.5M | 19.2M | 15.78M | 258K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 110.53M | 87.88M | 109.31M | 179.33M | 74.09M | 40.24M | 56.92M | 41.09M | 82.72M | 83.48M |
| Current Ratio | 1.12x | 1.24x | 1.30x | 1.39x | 2.49x | 1.85x | 1.55x | 3.43x | 3.97x | 3.97x |
| Quick Ratio | 0.96x | 1.07x | 1.09x | 1.04x | 2.23x | 1.50x | 1.22x | 3.13x | 3.52x | 3.52x |
| Cash Conversion Cycle | 55.98 | 56.63 | 58.01 | 89.7 | 55.99 | 57.62 | 52.37 | 86.65 | 73.13 | 87.97 |
| Total Non-Current Liabilities | 434.3M | 403M | 445.39M | 426.03M | 384.58M | 392.13M | 422.43M | 641.67M | 517.31M | 355.42M |
| Long-Term Debt | 134.88M | 167.15M | 259.86M | 225.83M | 190.16M | 219.47M | 222.03M | 422.18M | 370.53M | 123.02M |
| Capital Lease Obligations | 7.79M | 5.62M | 31.71M | 32.56M | 36.02M | 35.05M | 61.41M | 52.91M | 40.21M | 120.83M |
| Deferred Tax Liabilities | 148.73M | 115.2M | 118.72M | 137.21M | 148.49M | 126.43M | 126.77M | 140.8M | 126.24M | 484.47M |
| Other Non-Current Liabilities | 83.92M | 55.93M | 35.1M | 30.43M | 9.71M | 11.05M | 12.2M | 25.77M | -19.67M | 138.8M |
| Total Liabilities | 746.33M | 659.8M | 694.51M | 801.51M | 714.59M | 605.61M | 622.48M | 834.76M | 663.99M | 503.8M |
| Total Debt | 157.99M | 31.6M | 315.97M | 294.57M | 254.75M | 305.55M | 326.56M | 504.44M | 433.6M | 143.75M |
| Net Debt | 66.49M | -64.87M | 230.52M | 222.36M | 120.05M | 152.36M | 230.68M | 72.51M | 64.52M | -198.13M |
| Debt / Equity | 0.09x | 0.02x | 0.20x | 0.18x | 0.15x | 0.20x | 0.24x | 0.37x | 0.34x | 0.34x |
| Debt / EBITDA | - | - | - | 2.06x | 2.61x | - | - | - | - | -4.34x |
| Net Debt / EBITDA | - | - | - | 1.55x | 1.23x | - | - | - | - | 5.99x |
| Interest Coverage | -40.19x | -13.91x | -13.17x | 3.22x | 0.26x | -31.48x | -12.65x | 0.78x | -1.38x | -1.10x |
| Total Equity | 1.84B▲ 0% | 1.79B▼ 2.8% | 1.61B▼ 9.9% | 1.67B▲ 3.5% | 1.69B▲ 0.8% | 1.56B▼ 7.3% | 1.39B▼ 11.0% | 1.37B▼ 1.7% | 1.27B▼ 7.1% | 1.2B▲ 0% |
| Equity Growth % | -11.86% | -2.84% | -9.86% | 3.52% | 0.81% | -7.33% | -11.04% | -1.71% | -7.14% | -29.33% |
| Book Value per Share | 3.30 | 3.16 | 2.71 | 2.61 | 2.60 | 2.17 | 1.85 | 1.97 | 1.66 | 1.59 |
| Total Shareholders' Equity | 1.84B | 1.79B | 1.61B | 1.67B | 1.69B | 1.56B | 1.39B | 1.37B | 1.27B | 1.2B |
| Common Stock | 5.6M | 5.87M | 6.7M | 6.71M | 6.9M | 7.81M | 7.82M | 7.01M | 7.9M | 7.85M |
| Retained Earnings | -1.05B | -1.2B | -1.51B | -1.48B | -1.51B | -1.82B | -2.01B | -2.07B | -2.29B | -2.35B |
| Treasury Stock | -1.79M | -1.79M | -1.79M | -1.79M | -1.79M | -1.79M | -1.79M | -1.79M | -3.18M | 0 |
| Accumulated OCI | -528K | -20.13M | -22.07M | -4.22M | -30.5M | -43.32M | -38.03M | -56.13M | -21.02M | -27.49M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OPK Cash Flow Statement
OPKO Health, Inc. (OPK) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -92.08M | -109.14M | -172.52M | 39.48M | 38.34M | -95.19M | -28.2M | -183.49M | -178.54M | -178.54M |
| Operating CF Margin % | -9.53% | -11.02% | -19.13% | 2.75% | 2.16% | -9.48% | -3.27% | -25.73% | -29.42% | - |
| Operating CF Growth % | -387.34% | -18.53% | -58.07% | 122.88% | -2.89% | -348.3% | 70.38% | -550.74% | 2.7% | -74.77% |
| Net Income | -305.25M | -153.04M | -314.93M | 30.59M | -30.14M | -328.4M | -188.86M | -53.22M | -225.68M | -212.96M |
| Depreciation & Amortization | 102.09M | 97.34M | 93.81M | 85.36M | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M | 90.34M |
| Stock-Based Compensation | 28.31M | 21.76M | 13.42M | 8.95M | 13.63M | 18.51M | 11.41M | 11.05M | 10.71M | 10.83M |
| Deferred Taxes | 16.09M | -35.13M | 4.32M | 15.64M | 10.16M | -74.41M | 146K | 14.74M | -15M | -15.46M |
| Other Non-Cash Items | 18.33M | 18.07M | 99.66M | -3.45M | -13.54M | 137.8M | 22.01M | -286.41M | 976K | 15.79M |
| Working Capital Changes | 48.35M | -58.14M | -68.81M | -97.61M | -20.48M | 42.65M | 21.8M | 32.17M | -41.18M | -51.88M |
| Change in Receivables | 58.01M | 20.4M | 7.38M | -150.44M | 5.23M | 128.6M | 3.41M | -220K | 30.21M | 16.81M |
| Change in Inventory | -3.54M | 4.59M | -12.13M | -77.64M | 30.68M | 13.66M | 15.2M | 4.22M | -4.12M | 1.51M |
| Change in Payables | 20.17M | -26.08M | 15.64M | 37.16M | -10.85M | -9.39M | 2.83M | -20.66M | -14.22M | -22.2M |
| Cash from Investing | -46.67M | -26.12M | -13.27M | -18.33M | 35.95M | 91.04M | -18.2M | 352.21M | 230.3M | 187.97M |
| Capital Expenditures | -46.52M | -27.86M | -12.74M | -33.68M | -32.16M | -24.58M | -16.27M | -25.01M | -12.28M | -10.92M |
| CapEx % of Revenue | 4.82% | 2.81% | 1.41% | 2.35% | 1.81% | 2.45% | 1.88% | 3.51% | 2.02% | - |
| Acquisitions | -9.63M | -1M | -1.2M | 0 | -6M | -1.76M | -5M | 0 | 0 | 197.77M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -39.25M | -26.64M | 671K | 245K | 66.03M | 1.95M | 2.71M | 210.62M | 190.39M | 588K |
| Cash from Financing | 61.04M | 140.91M | 175.25M | -35.08M | -10.35M | 22.97M | -11.3M | 184.17M | -118.06M | -119.19M |
| Debt Issued (Net) | 58.91M | 47.24M | 106.95M | -35.83M | -11.24M | 23.75M | -11.03M | 287.98M | -70.76M | -66.65M |
| Equity Issued (Net) | 0 | 92.5M | 76.06M | 0 | 0 | 0 | 0 | -90.22M | -47.3M | -47.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -90.22M | -47.04M | -47.04M |
| Other Financing | 2.13M | 1.17M | -7.76M | 756K | 893K | -774K | -272K | -13.59M | 0 | -5.16M |
| Net Change in Cash | -77.23M▲ 0% | 4.97M▲ 106.4% | -11.02M▼ 321.6% | -13.24M▼ 20.1% | 62.5M▲ 572.0% | 18.48M▼ 70.4% | -57.31M▼ 410.1% | 349.73M▲ 710.2% | -62.87M▼ 118.0% | -94.11M▲ 0% |
| Free Cash Flow | -138.6M▲ 0% | -137M▲ 1.2% | -185.26M▼ 35.2% | 5.79M▲ 103.1% | 6.18M▲ 6.7% | -119.77M▼ 2037.7% | -44.47M▲ 62.9% | -208.5M▼ 368.8% | -190.82M▲ 8.5% | -174.22M▲ 0% |
| FCF Margin % | -14.35% | -13.83% | -20.54% | 0.4% | 0.35% | -11.93% | -5.15% | -29.24% | -31.44% | -29.98% |
| FCF Growth % | -1730.83% | 1.16% | -35.23% | 103.13% | 6.68% | -2037.66% | 62.87% | -368.83% | 8.48% | 15.53% |
| FCF per Share | -0.25 | -0.24 | -0.31 | 0.01 | 0.01 | -0.17 | -0.06 | -0.30 | -0.25 | -0.25 |
| FCF Conversion (FCF/Net Income) | 0.30x | 0.71x | 0.55x | 1.29x | -1.27x | 0.29x | 0.15x | 3.45x | 0.79x | 0.82x |
| Interest Paid | 1.31M | 0 | 11.87M | 10.91M | 8.52M | 7.42M | 8.13M | 20.88M | 0 | 16.44M |
| Taxes Paid | 5.42M | 0 | 2.67M | 903K | 5.97M | 8.04M | 3.71M | 10.01M | 0 | 18.57M |
OPK Key Ratios
OPKO Health, Inc. (OPK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -15.51% | -8.42% | -18.49% | 1.86% | -1.8% | -20.23% | -12.8% | -3.86% | -17.14% | -16.79% |
| Return on Invested Capital (ROIC) | -10.53% | -7.06% | -11.51% | 2.32% | 0.76% | -9.64% | -7.06% | -7.46% | -11.86% | -11.86% |
| Gross Margin | 35.8% | 38.95% | 36.53% | 37.69% | 32.77% | 28.7% | 36.84% | 43.61% | 21.1% | 47.7% |
| Net Margin | -31.6% | -15.45% | -34.92% | 2.13% | -1.7% | -32.7% | -21.87% | -7.46% | -37.2% | -36.64% |
| Debt / Equity | 0.09x | 0.02x | 0.20x | 0.18x | 0.15x | 0.20x | 0.24x | 0.37x | 0.34x | 0.34x |
| Interest Coverage | -40.19x | -13.91x | -13.17x | 3.22x | 0.26x | -31.48x | -12.65x | 0.78x | -1.38x | -1.10x |
| FCF Conversion | 0.30x | 0.71x | 0.55x | 1.29x | -1.27x | 0.29x | 0.15x | 3.45x | 0.79x | 0.82x |
| Revenue Growth | -20.93% | 2.51% | -8.92% | 59.15% | 23.64% | -43.42% | -14.01% | -17.41% | -14.9% | -15.7% |
OPK SEC Filings & Documents
OPKO Health, Inc. (OPK) SEC filings — annual & quarterly reports (10-K, 10-Q)
OPK Frequently Asked Questions
OPKO Health, Inc. (OPK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OPKO Health, Inc. (OPK) reported $581.2M in revenue for fiscal year 2025. This represents a 581072% increase from $0.1M in 1996.
OPKO Health, Inc. (OPK) saw revenue decline by 14.9% over the past year.
OPKO Health, Inc. (OPK) reported a net loss of $213.0M for fiscal year 2025.
Dividend & Returns
OPKO Health, Inc. (OPK) has a return on equity (ROE) of -17.1%. Negative ROE indicates the company is unprofitable.
OPKO Health, Inc. (OPK) had negative free cash flow of $174.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More OPK
OPKO Health, Inc. (OPK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates